SFI
CRBP icon

Susquehanna Fundamental Investments’s Corbus Pharmaceuticals CRBP Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,277
Closed -$39K – 1498
2021
Q3 		$39K Sell
1,277
-491
-28% -$19.4K ﹤0.01% 1664
2021
Q2 		$97K Sell
1,768
-5,119
-74% -$284K ﹤0.01% 1573
2021
Q1 		$407K Buy
+6,887
New +$453K 0.01% 1210

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Susquehanna Fundamental Investments's CRBP Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Corbus Pharmaceuticals (CRBP) in Q4 2021, closing a stake of 1,277 shares — an estimated $39K sold.

Susquehanna Fundamental Investments first reported a position in CRBP in Q1 2021 and held it in 3 quarters. The position peaked at $407K in Q1 2021. 82 funds tracked by Wall St. Rank hold CRBP as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining Corbus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 1,277 Corbus Pharmaceuticals shares in Q4 2021, an estimated $39K.
  • Susquehanna Fundamental Investments first reported a position in Corbus Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Corbus Pharmaceuticals position peaked at $407K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.